English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 8 January 2013, 08:00 HKT/SGT

Source: INC Research, LLC
Jamie Macdonald Assumes CEO Role at INC Research; Succession Plan Complete

Raleigh, NC, Jan 8, 2013 - (ACN Newswire) - INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process(R) for delivering reliable results, today reported the completion of its CEO succession plan announced in August 2012.

Effective Jan. 1, 2013, Jamie Macdonald, formerly Chief Operating Officer for the Company, officially assumed the role of INC Research's new Chief Executive Officer. Mr. Macdonald replaced James T. Ogle, who remains with the Company as Chairman of the Board. Alistair Macdonald, previously President, Clinical Development Services, assumed the role of Chief Operating Officer.

"With the completion of these changes and the additional executive appointments made in recent months, INC Research is strategically positioned for continued growth," said James Ogle, Chairman of the Board. "We greatly appreciate Jamie and Alistair's contributions to date and look forward to their future leadership as we continue to advance INC Research as a leading provider of clinical development solutions globally."

"I am excited about 2013 and the opportunities it holds for INC Research and our customers," noted Jamie Macdonald, Chief Executive Officer for the Company. "We will continue to leverage our enhanced global scale, renowned therapeutic capability and enhanced Trusted Process(R) to offer increasingly innovative clinical development solutions that improve efficiency and ultimately lead our customers to make better decisions faster. The future for our industry and our Company has never been brighter and we look forward to continuing to partner with our customers in the delivery of new medicines to market to improve world health."

About INC Research

INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical developmentprograms of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process(R) methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.

Contact: Lori Dorer, Media +1-513-345-1685

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: INC RESEARCH, LLC via Thomson Reuters ONE

Topic: Press release summary

From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


INC Research, LLC Releated News
Nov 7, 2014 08:50 HKT/SGT
INC Research Announces Pricing of Initial Public Offering
Oct 7, 2014 07:10 HKT/SGT
INC Research Files Registration Statement for Initial Public Offering
Oct 3, 2014 10:30 HKT/SGT
INC Research Demonstrates Continued Dedication to Site Relationships at 2014 SCRS Site Solutions Summit
Oct 2, 2014 07:20 HKT/SGT
INC Research Further Reinforces Commitment to Clinical Research Sites and Patients through Creation of New Leadership Role
Aug 6, 2014 03:30 HKT/SGT
INC Research's Tara Fitzgerald and Judy Swilley Named to Annual PharmaVOICE 100
More news >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: